Physician profile
Thomas J Markus
NPI 1467419903
$2,016.00
in general payments reported to CMS, 2019-2025
23 companies · $357 in 2025
The $357 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $301 · 2020: $101 · 2021: $270 · 2022: $335 · 2023: $382 · 2024: $269 · 2025: $357.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,008.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,007.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $410.93 | 2022-2025 | |
| Oyster Point Pharma, INC. | $261.46 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Allergan, INC. | $194.15 | 2019-2021 | |
| Shire North American Group INC | $141.05 | 2019 | |
| Alcon Vision LLC | $125.10 | 2022-2025 | Precision7, Tryptyr, Rocklatan |
| Bausch & Lomb Americas INC. | $121.14 | 2022-2024 | Xiidra, Vyzulta, Miebo |
| Sun Pharmaceutical Industries INC. | $104.53 | 2019-2020 | |
| Harrow Eye, LLC | $104.22 | 2025 | Vevye, Ilevro |
| Horizon Therapeutics Plc | $88.74 | 2021-2023 | Tepezza |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $57.19 | 2019-2021 | |
| Aerie Pharmaceuticals, INC. | $56.97 | 2020-2021 | |
| Genentech USA, INC. | $51.97 | 2025 | Vabysmo |
| Thea Pharma INC. | $48.13 | 2024-2025 | Iyuzeh |
| Dompe US, INC. | $45.89 | 2022 | |
| Akorn Operating Company LLC | $41.61 | 2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tarsus Pharmaceuticals, INC. | $38.18 | 2025 | Xdemvy |
| Biogen, INC. | $22.45 | 2022 | |
| Novartis Pharmaceuticals Corporation | $21.35 | 2022 | |
| Eyevance Pharmaceuticals LLC | $18.05 | 2019 | |
| Kala Pharmaceuticals, INC. | $16.21 | 2022 | |
| Sight Sciences, INC. | $15.90 | 2022 | |
| Akorn, INC. | $15.81 | 2020 | |
| Astellas Pharma US INC | $14.97 | 2024 | Izervay |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Markus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.